Christoph Leisser1, Nino Hirnschall1, Christoph Hackl1, Pia Plasenzotti2, Oliver Findl1,3. 1. VIROS-Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna - Austria. 2. 1 Medical Department, Hanusch Hospital, Vienna - Austria. 3. Moorfields Eye Hospital NHS Foundation Trust, London - UK.
Abstract
PURPOSE: To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC). METHODS: In this retrospective case series, 11 patients with chronic recurring CSC were included. The main focus was to include patients who had undergone photodynamic therapy (4 patients), had undergone anti-vascular endothelial growth factor treatment (3 patients), or had several episodes of CSC in the past (4 patients) (mean age 60 years; SD 9.7, range 47-76). RESULTS: Four patients (36.4%) had full resorption of neurosensory detachment under therapy of eplerenone with improvement of vision, while 4 more patients had improvement of vision despite residual edema. Eight patients (73%) had improved visual acuity (VA) at the end of eplerenone therapy, 2 patients had no change in VA, and 1 patient decreased VA. Mean time of treatment was 10.6 ± 9.9 weeks (range 3-38 weeks). All patients showed subretinal deposits, with 6 of them having hyperautofluorescent subretinal deposits. CONCLUSIONS: Eplerenone represents a new treatment option for patients with CSC. Our data indicate a good response in those patients, leading to improvement of VA in 73% of patients.
PURPOSE: To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC). METHODS: In this retrospective case series, 11 patients with chronic recurring CSC were included. The main focus was to include patients who had undergone photodynamic therapy (4 patients), had undergone anti-vascular endothelial growth factor treatment (3 patients), or had several episodes of CSC in the past (4 patients) (mean age 60 years; SD 9.7, range 47-76). RESULTS: Four patients (36.4%) had full resorption of neurosensory detachment under therapy of eplerenone with improvement of vision, while 4 more patients had improvement of vision despite residual edema. Eight patients (73%) had improved visual acuity (VA) at the end of eplerenone therapy, 2 patients had no change in VA, and 1 patient decreased VA. Mean time of treatment was 10.6 ± 9.9 weeks (range 3-38 weeks). All patients showed subretinal deposits, with 6 of them having hyperautofluorescent subretinal deposits. CONCLUSIONS:Eplerenone represents a new treatment option for patients with CSC. Our data indicate a good response in those patients, leading to improvement of VA in 73% of patients.
Authors: R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques Journal: Eye (Lond) Date: 2018-01-05 Impact factor: 3.775